A semi-solid drug delivery system for epidermal growth factor in corneal epithelial wound healing
- 1 January 1997
- journal article
- Published by Taylor & Francis in Current Eye Research
- Vol. 16 (3) , 183-190
- https://doi.org/10.1076/ceyr.16.3.183.15403
Abstract
Purpose. To examine the effects of EGF, delivered from a semi-solid drug delivery system, on corneal epithelial wound healing following anterior keratectomy wound creation in the eyes of New Zealand white rabbits. Methods. A semi-solid drug delivery system based on a Carbopol gel was developed. Following creation of a 7.5 mm circular anterior keratectomy wound, 50 µL of either a placebo gel or an EGF-containing gel, was instilled in the inferior fornix. The gel remained in the eye for 8 hours, at which time it was removed. Anaesthesia was maintained for the entire 8-hour period. Wound healing was evaluated by quantitative morphometry. We evaluated 0.04, 0.1, 0.2, 0.4, and 1% EGF concentrations in the gel. Tear EGF concentrations and histology of the healing corneas were also examined. Results. The enhancement factor (ratio of the healing rate with the EGF gel and control gel) was 1.13 ± 0.12, 1.40 ± 0.14, 1.29 ± 0.12, 1.80 ± 0.22, and 1.09 ± 0.12 for the gels containing 0.04, 0.1, 0.2, 0.4, and 1% EGF by mass, respectively. The increases in the rate of wound healing were significant with the 0.1, 0.2 and 0.4% gel formulations. Histologically, the 0.4% gels resulted in cellular hyperplasia after 5 days of healing. Differences between the placebo gel-treated and EGF-containing gel-treated eyes were evaluated at both 2 and 5 days. The concentration of EGF in the tears during the treatment period was approximately constant for both the 1% and 0.04% gels. The average tear concentration during the instillation period was 2.87 ± 0.36 µg/mL and 200.61 ng/mL ± 116.10 for the 1% and 0.04% gels respectively. Conclusions. Treatment with EGF in a Carbopol gel carrier for a period of 8 hours results in significant wound healing enhancement (p < 0.05). The optimum EGF loading in the gel was determined to be 0.4%. A slow release gel may be an effective way to deliver EGF to the corneal surface.Keywords
This publication has 16 references indexed in Scilit:
- Effects of epidermal growth factor dosage forms on dermal wound strength in miceJournal of Pharmacy and Pharmacology, 1994
- In Situ-Forming Gels for Ophthalmic Drug DeliveryJournal of Ocular Pharmacology and Therapeutics, 1994
- Epidermal growth factor in human tear fluid: Increased release but decreased concentrations during reflex tearingCurrent Eye Research, 1990
- Stability of recombinant human epidermal growth factor in various solutions.CHEMICAL & PHARMACEUTICAL BULLETIN, 1989
- Acceleration of Tensile Strength of Incisions Treated with EGF and TGF-βAnnals of Surgery, 1988
- The Effect of Epidermal Growth Factor on Epithelial Healing After Penetrating Keratoplasty in Human EyesAmerican Journal of Ophthalmology, 1984
- Bioadhesive polymers as platforms for oral-controlled drug delivery: method to study bioadhesionInternational Journal of Pharmaceutics, 1984
- A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligandsCell, 1981
- Production and characterization of antibody blocking epidermal growth factor: Receptor interactionsBiochimica et Biophysica Acta (BBA) - Biomembranes, 1980
- Selective binding of the epidermal growth factor and its specific effects on the epithelial cells of the corneaExperimental Eye Research, 1972